Stock 2181 MABPHARM LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Mabpharm Limited

Equities

2181

KYG5780F1046

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:05 2024-05-31 am EDT 		5-day change 1st Jan Change
0.345 HKD -.--% Intraday chart for Mabpharm Limited -.--% -25.00%
Mar. 26 Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 10 Livzon Pharma Recognizes Credit, Asset Impairments MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Livzon Pharma Recognizes Credit, Asset Impairments
MT
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use
MT
Mabpharm Limited Announces Director Changes
CI
Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2023
CI
China Grants Nod to Livzon Pharmaceutical Subsidiary's Clinical Trials for SARS-CoV-2 Booster Shot
MT
Livzon Pharma Raises Cap in Extended Purchase Agreement to 39 Million Yuan
MT
China Gives New Drug Application Approval to Mabpharm's Anti-Asthma Therapy
MT
Mabpharm Grants Jemincare Pharma Unit Promotion Rights to Asthma Drug
MT
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Chinese Regulator Accepts Mabpharm's New Drug Application for Colorectal Cancer Treatment
MT
Mabpharm Limited Announces New Drug Application of CMAB009
CI
Livzon Pharma's COVID vaccine gets approval as booster in China
RE
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2022
CI
China Approves Clinical Trials for Mabpharm's Psoriasis Treatment
MT
Mabpharm Limited Approves the Clinical Trial Application of CMAB015 for the Treatment of Psoriasis and Ankylosing Spondylitis
CI
Chinese Regulator Approves Mabpharm's Clinical Trial for New Drug
MT
Mabpharm Limited Announces Approval by National Medical Products Administration of China for the Clinical Trial Application of Biological Class I New Drug Cmab017
CI
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2181 Stock
  4. News Mabpharm Limited